AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) as they navigate drug pricing reforms and evolving pipelines.

AbbVie has successfully diversified its portfolio beyond its historic blockbuster Humira, while Pfizer is aggressively deploying capital from its pandemic-era windfall into new oncology and obesity treatments. Both companies are cornerstones of many income-focused portfolios, yet they offer distinct risk profiles for those seeking healthcare exposure.

The case for AbbVie

According to its latest annual report, AbbVie focuses on high-growth therapeutic areas like immunology, neuroscience, and aesthetics within the pharmaceutical stocks universe. Its recent growth is driven largely by two key immunology drugs which together represented nearly 42% of its revenue in 2025. The company distributes its products through major wholesalers including McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR). Customer concentration like this adds a layer of risk to the business.

In FY 2025, revenue reached nearly $61.2 billion, representing an increase of approximately 9% compared to the prior year. This growth is notable as the company successfully offset the declining sales of its former top-selling drug Humira. Net income for the period was roughly $4.2 billion, which is a slight decrease from the previous year. Still, this performance shows the ability to maintain top-line growth even as older products face competitive pressure.

As of its December 2025 balance sheet, the debt-to-equity ratio is -21.1x, which means total liabilities exceed shareholder equity. The so-called current ratio is roughly 0.7x, a metric that measures a company's ability to cover its short-term obligations with its short-term assets. Free cash flow, which is cash from operations minus capital expenditures, was approximately $17.8 billion for the fiscal year.

The case for Pfizer

Pfizer applies its global resources to develop and manufacture a wide range of vaccines and medicines for patients in roughly 200 countries. In its latest annual report, Pfizer details how it applies its scientific resources to develop a wide array of medicines and vaccines for global distribution, including how the company is currently focused on expanding its oncology pipeline through significant acquisitions such as Seagen. It also relies on key products like Eliquis, which accounted for approximately 13% of its total revenue in 2025.

In FY 2025, revenue reached nearly $62.6 billion, a decline of roughly 1.6% from the previous year. This slight contraction reflects the ongoing normalization of its business after the height of the pandemic. Net income for the year was approximately $7.8 billion, a substantial increase compared to the results reported two years prior.

As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.8x. This ratio shows the proportion of debt a company uses relative to the equity provided by its shareholders, offering insight into its financial leverage. The current ratio is roughly 1.2x, and free cash flow for the year reached nearly $9.1 billion, supporting its ongoing dividend payments and internal research initiatives.

Risk profile comparison

AbbVie faces intense pressure from the loss of patent protection for its key products as biosimilars enter the market. The Inflation Reduction Act also introduces risks by allowing the government to set prices for several of its high-expenditure drugs, including Botox and Vraylar. Furthermore, the company relies on complex international supply chains where any disruption or failure to meet regulatory standards could result in product shortages.

Pfizer is navigating a period of significant patent expirations that could reduce revenue between 2026 and 2030. It is also subject to ongoing legal proceedings, including product liability claims and patent disputes, which may result in financial settlements or loss of exclusivity. Failure to successfully launch new products from its research and development pipeline could also impact its future financial results and valuation.

Valuation comparison

Pfizer appears to be the more value-oriented option based on its lower Forward P/E, while AbbVie carries a higher P/S ratio following its recent growth.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

AbbVie is buying itself growth with its recent deal to acquire Apogee Therapeutics (NASDAQ:APGE). Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson's treatment later this year will bode well for the company. AbbVie is expected to see screaming growth in net income this year, from $4.2 billion to $14.6 billion. Sales should grow to $67.2 billion.

AbbVie has a drug pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) for treating schizophrenia, Parkinson's disease, psychosis from Alzheimer's, and certain solid tumors.

Pfizer has been in an odd spot in recent years, as the boost it got from its COVID-19 vaccines is wearing off, with fewer people getting them and competitors proliferating. Wall Street has also been concerned about a "wall" of patent expirations facing the business in the next few years.

But there is reason for hope. Pfizer has made great strides in bringing its own GLP-1s to market. In December, it struck a deal with a Chinese pharmaceutical company to develop small-molecule GLP-1s that will lead to a daily pill. Plus its recent acquisitions have driven overall growth for the company.

For fiscal 2026, net income is seen jumping by some 40% to more than $11 billion, with sales increasing by a smaller margin to $61.7 billion. Sales beyond are expected to decline due to expiring patents, but the company is expecting three FDA decisions and multiple trial readouts and starts that should generate at least some new products to power the business.

AbbVie is in excellent shape, but Pfizer appears to be a value play for those willing to hold onto shares through a period of seeing new drugs come to market. With its lower P/S and forward P/E rations, Pfizer is the choice for long-term investors.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.